{"id":37411,"date":"2026-11-17T12:35:08","date_gmt":"2026-11-17T12:35:08","guid":{"rendered":"https:\/\/demo.tcjhomeaccents.com\/wp\/2026\/11\/17\/isomorphic-labs-raises-5bn-from-sequoia-and-greenoaks-for-ai-drug-design\/"},"modified":"2026-11-17T12:35:08","modified_gmt":"2026-11-17T12:35:08","slug":"isomorphic-labs-raises-5bn-from-sequoia-and-greenoaks-for-ai-drug-design","status":"publish","type":"post","link":"https:\/\/demo.tcjhomeaccents.com\/wp\/2026\/11\/17\/isomorphic-labs-raises-5bn-from-sequoia-and-greenoaks-for-ai-drug-design\/","title":{"rendered":"Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design"},"content":{"rendered":"<p>Demis Hassabis at the World Economic Forum in Davos, January 2025 Credit: World Economic Forum \/ Gabriel Lado \/ CC BY-NC-SA 2.0 via Flickr (cropped) Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital. The company announced the round on Tuesday, six months after it raised $2.1bn in May. Andreessen Horowitz and several other new investors joined, with what Isomorphic called continued significant investment from Alphabet. All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.<\/p>\n<p>Isomorphic said investors oversubscribed the round. The company did not disclose its valuation, Bloomberg reported. Bloomberg had reported this month that the round would value Isomorphic at about $50bn. \u2018Hundreds of drugs a year\u2019 Hassabis told Bloomberg\u2019s Rebecca Torrence and Shirin Ghaffary that the money will speed up Isomorphic\u2019s move towards clinical trials. \u201cWhat we\u2019re trying to build is a platform to do hundreds of drugs a year,\u201d Hassabis told Bloomberg. Isomorphic said its drug design engine, IsoDDE, is producing positive preclinical results in its own oncology and immunology programmes and with partners.<\/p>\n<p>It has more than 20 programmes underway, Hassabis said. Its pharma partners include Eli Lilly, Novartis and Johnson &amp; Johnson. In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. He would not give Bloomberg an updated target.<\/p>\n<p>He said the company is on track with its regulatory submissions and will have more to announce in 2027. No regulator has yet approved an AI-designed drug, Bloomberg noted. Isomorphic will also use the money to move beyond small-molecule drugs into \u201cpretty much all modalities\u201d, Hassabis said, including large-molecule biologics. The backers \u201cIsomorphic Labs is building foundational technology for the future of medicine,\u201d said Konstantine Buhler, a partner at Sequoia Capital.<\/p>\n<p>Buhler told Bloomberg that Sequoia backed the company because Isomorphic has found scaling laws for its models. That means performance keeps improving with more computing power and data, he said. The round is Isomorphic\u2019s first since Hassabis stepped back as Google DeepMind\u2019s chief executive in August, in an Alphabet shake-up. He is now DeepMind\u2019s chair and Alphabet\u2019s chief scientist, and remains Isomorphic\u2019s chief executive.<\/p>\n<p>He also addressed computing power. Jensen Huang\u2019s resignation from Nvidia last week has some AI companies worried about their access to chips, Bloomberg reported. Google designs its own AI chips. \u201cWe\u2019ve got very secure compute pipelines,\u201d Hassabis told Bloomberg. Isomorphic started in 2021 to build on Google DeepMind\u2019s AlphaFold protein structure model.<\/p>\n<p>It has its headquarters in London and offices in Cambridge, Massachusetts, and Lausanne. Get the TNW newsletter \u2715 Close Get the TNW newsletter Get the most important tech news in your inbox each week.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Demis Hassabis at the World Economic Forum in Davos, January 2025 Credit: World Economic Forum \/ Gabriel Lado \/ CC BY-NC-SA 2.0 via Flickr (cropped) Isomorphic Labs, the Alphabet drug discovery company run by Demis\u2026<\/p>\n","protected":false},"author":1,"featured_media":37412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-37411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/posts\/37411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/comments?post=37411"}],"version-history":[{"count":0,"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/posts\/37411\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/media\/37412"}],"wp:attachment":[{"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/media?parent=37411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/categories?post=37411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/demo.tcjhomeaccents.com\/wp\/wp-json\/wp\/v2\/tags?post=37411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}